These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11818704)

  • 41. Treatment of reduced bone density with ibandronate in dialysis patients.
    Bergner R; Henrich D; Hoffmann M; Schmidt-Gayk H; Lenz T; Upperkamp M
    J Nephrol; 2008; 21(4):510-6. PubMed ID: 18651540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism.
    Wu CC; Chang JH; Chen CC; Su SB; Yang LK; Ma WY; Zheng CM; Diang LK; Lu KC
    Tohoku J Exp Med; 2011 Mar; 223(3):153-9. PubMed ID: 21350317
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pulse dose oral calcitriol therapy for renal osteodystrophy: literature review and practice recommendations.
    Dahl NV; Foote EF
    ANNA J; 1997 Oct; 24(5):550-5. PubMed ID: 9392738
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
    Sahota O; Fowler I; Blackwell PJ; Lawson N; Cawte SA; San P; Masud T; Hosking DJ
    Osteoporos Int; 2000; 11(11):959-66. PubMed ID: 11193249
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of chronic inflammation on bone turnover in hemodialysis patients.
    Eleftheriadis T; Kartsios C; Antoniadi G; Kazila P; Dimitriadou M; Sotiriadou E; Koltsida M; Golfinopoulos S; Liakopoulos V; Christopoulou-Apostolaki M
    Ren Fail; 2008; 30(4):431-7. PubMed ID: 18569918
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
    Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
    Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
    Rauscher S; Lafrance JP; Pichette V; Bell RZ; Desforges K; Lepage L; Ouellet G; Ouimet D; Leblanc M; Lamarche C; Bezzaoucha S; Vallee M
    Int Urol Nephrol; 2017 Feb; 49(2):325-328. PubMed ID: 27822674
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate.
    Khajehdehi P; Taheri S
    J Ren Nutr; 2003 Apr; 13(2):78-83. PubMed ID: 12671829
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses.
    Koshikawa S; Akizawa T; Kurokawa K; Marumo F; Sakai O; Arakawa M; Morii H; Seino Y; Ogata E; Ohashi Y; Akiba T; Tsukamoto Y; Suzuki M
    Nephron; 2002 Apr; 90(4):413-23. PubMed ID: 11961400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.
    Cozzolino M; Brancaccio D; Cannella G; Messa P; Gesualdo L; Marangella M; LoDeserto C; Pozzato M; Rombolà G; Costanzo AM; di Luzio Paparatti U; Mazzaferro S;
    Nephrol Dial Transplant; 2012 Sep; 27(9):3588-94. PubMed ID: 22523119
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
    Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A
    Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
    Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
    Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.
    Teng M; Wolf M; Lowrie E; Ofsthun N; Lazarus JM; Thadhani R
    N Engl J Med; 2003 Jul; 349(5):446-56. PubMed ID: 12890843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Pulsed doses of calcitriol in the treatment of secondary hyperparathyroidism in patients on hemodialysis].
    Sotorník I; Petrásek R; Schück O; Adamec M; Smrcková I; Tocík J
    Vnitr Lek; 1997 Sep; 43(9):584-91. PubMed ID: 9750467
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients.
    Dogan E; Erkoc R; Sayarlioglu H; Soyoral Y; Dulger H
    Ren Fail; 2008; 30(4):407-10. PubMed ID: 18569914
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients.
    Bajo MA; Selgas R; Possante C; Aguilera A; Sánchez C; Diaz C; de Alvaro F; Martinez ME
    Adv Perit Dial; 1997; 13():239-43. PubMed ID: 9360690
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravenous calcitriol can increase bone mass in hemodialysis patients with osteitis fibrosa.
    Akiba T; Kurihara S; Yamada T; Ogasawara M; Yoneshima H; Marumo F
    Miner Electrolyte Metab; 1995; 21(1-3):109-13. PubMed ID: 7565429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.